Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardiff Oncology (CRDF) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Cardiff Oncology (CRDF) over the last 16 years, with Q3 2025 value amounting to $66.9 million.

  • Cardiff Oncology's Shares Outstanding (Weighted Average) rose 4270.56% to $66.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $66.9 million, marking a year-over-year increase of 4270.56%. This contributed to the annual value of $47.6 million for FY2024, which is 665.44% up from last year.
  • According to the latest figures from Q3 2025, Cardiff Oncology's Shares Outstanding (Weighted Average) is $66.9 million, which was up 4270.56% from $66.5 million recorded in Q2 2025.
  • In the past 5 years, Cardiff Oncology's Shares Outstanding (Weighted Average) registered a high of $66.9 million during Q3 2025, and its lowest value of $37.2 million during Q1 2021.
  • Over the past 5 years, Cardiff Oncology's median Shares Outstanding (Weighted Average) value was $44.7 million (recorded in 2023), while the average stood at $46.9 million.
  • As far as peak fluctuations go, Cardiff Oncology's Shares Outstanding (Weighted Average) skyrocketed by 27501.51% in 2021, and later increased by 0.22% in 2024.
  • Quarter analysis of 5 years shows Cardiff Oncology's Shares Outstanding (Weighted Average) stood at $39.0 million in 2021, then increased by 11.71% to $43.6 million in 2022, then grew by 2.47% to $44.7 million in 2023, then increased by 6.65% to $47.6 million in 2024, then surged by 40.35% to $66.9 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $66.9 million in Q3 2025, compared to $66.5 million in Q2 2025 and $66.5 million in Q1 2025.